ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 748

Increased Expression of Chemerin in Endothelial Cells Due to Fli1 Deficiency May Contribute to the Development of Digital Ulcers in Systemic Sclerosis

Kaname Akamata, Yoshihide Asano, Takashi Taniguchi, Hayakazu Sumida, Naohiko Aozasa, Shinji Noda, Tetsuo Toyama, Takehiro Takahashi, Yohei Ichimura, Ayumi Yoshizaki and Shinichi Sato, Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disorder characterized by vascular injuries and fibrosis development. In SSc lesional skin, transcription factor Friend leukemia virus integration 1 (Fli1) is constitutively down-regulated in various cell types, especially by an epigenetic mechanism in dermal fibroblasts, and Fli1 deficiency is deeply related to the pathogenesis of SSc. In particular, endothelial Fli1 deficiency reproduces the histological and functional abnormalities characteristic of SSc vasculopathy in vivo. Recently, adipocytokines have drawn much attention in the research field of various autoimmune diseases. Chemerin is a member of adipocytokines with a chemoattractant effect and a pro-angiogenic property, and has been shown to have pivotal roles in the pathogenesis of various autoimmune diseases. To elucidate the role of chemerin in the developmental process of SSc, we investigated the expression levels of chemerin in SSc lesional skin and the mechanism underlying its altered expression, and the clinical correlation of serum chemerin levels in SSc patients.

Methods: Expression of chemerin and its receptor, ChemR23, was evaluated by immunostaining and/or quantitative reverse transcription-real time PCR in human and/or murine skin. The mechanisms regulating chemerin expression in dermal fibroblasts and endothelial cells were examined by gene silencing technique and chromatin immunoprecipitation. Serum chemerin levels were determined by enzyme-linked immunosorbent assay in 64 SSc and 19 healthy subjects.

Results: In SSc lesional skin, chemerin was up-regulated in small blood vessels, down-regulated in activated fibroblasts surrounded with thickened collagen bundles, but not altered in inflammatory cells, while ChemR23 expression was comparable in various cell types. Chemerin expression was also markedly decreased in dermal fibroblasts of bleomycin-treated SSc model mice. Importantly, the decreased expression of chemerin was significantly reversed by blocking autocrine transforming growth factor (TGF)-β signaling with TGF-β1 antisense oligonucleotide in cultured SSc dermal fibroblast. As for endothelial cells, gene silencing of Fli1, which directly bound to the chemerin promoter, induced chemerin expression in human dermal microvascular endothelial cells and Fli1+/- mice exhibited elevated chemerin expression in dermal blood vessels. Regarding the correlation of serum chemerin levels with clinical features in SSc patients, serum chemerin levels inversely correlated with estimated glomerular filtration rate in SSc patients with renal dysfunction while, in SSc patients with normal renal function, patients with digital ulcers had higher serum chemerin levels than those without.

Conclusion: Chemerin is down-regulated in SSc dermal fibroblasts by autocrine TGF-β, while up-regulated in SSc dermal blood vessels through endothelial Fli1 deficiency. In SSc, dysregulated chemerin/ChemR23 axis by endothelial Fli1 deficiency may contribute to the development of SSc vasculopathy through altering angiogenic/angiostatic signaling pathways.


Disclosure:

K. Akamata,
None;

Y. Asano,
None;

T. Taniguchi,
None;

H. Sumida,
None;

N. Aozasa,
None;

S. Noda,
None;

T. Toyama,
None;

T. Takahashi,
None;

Y. Ichimura,
None;

A. Yoshizaki,
None;

S. Sato,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-expression-of-chemerin-in-endothelial-cells-due-to-fli1-deficiency-may-contribute-to-the-development-of-digital-ulcers-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology